- Home
- GL vs MRNA Comparison
GL vs MRNA Comparison
Compare GL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GL | MRNA |
|---|---|---|
| Founded | 1900 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 11.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GL | MRNA |
|---|---|---|
| Price | $139.94 | $30.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 14 |
| Target Price | ★ $160.00 | $33.25 |
| AVG Volume (30 Days) | 482.1K | ★ 9.8M |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 16.72 | N/A |
| EPS | ★ 13.77 | N/A |
| Revenue | ★ $5,940,974,000.00 | $2,232,000,000.00 |
| Revenue This Year | $7.48 | N/A |
| Revenue Next Year | $5.31 | $0.77 |
| P/E Ratio | $10.13 | ★ N/A |
| Revenue Growth | ★ 3.73 | N/A |
| 52 Week Low | $103.71 | $22.28 |
| 52 Week High | $147.83 | $48.92 |
Technical Indicators
Market Signals| Indicator | GL | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 69.17 | 68.23 |
| Support Level | $130.07 | $26.90 |
| Resistance Level | $132.02 | $30.44 |
| Average True Range (ATR) | 2.24 | 1.20 |
| MACD | 1.01 | 0.59 |
| Stochastic Oscillator | 89.67 | 95.63 |
Price Performance
Historical ComparisonAbout GL Globe Life Inc.
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.